RCM
SPRY icon

RA Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

RA Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87M Hold
10,860,977
– – 0.76% 27
2026
Q1 		$87.2M Hold
10,860,977
– – 0.92% 24
2025
Q4 		$127M Hold
10,860,977
– – 1.3% 18
2025
Q3 		$109M Hold
10,860,977
– – 1.35% 20
2025
Q2 		$190M Hold
10,860,977
– – 3.19% 8
2025
Q1 		$137M Hold
10,860,977
– – 2.28% 11
2024
Q4 		$115M Hold
10,860,977
– – 1.52% 17
2024
Q3 		$157M Hold
10,860,977
– – 1.82% 15
2024
Q2 		$92.4M Hold
10,860,977
– – 1.22% 22
2024
Q1 		$111M Buy
10,860,977
+1,401,299
+15% +$10.4M 1.41% 22
2023
Q4 		$51.8M Hold
9,459,678
– – 0.81% 30
2023
Q3 		$35.8M Buy
9,459,678
+6,450,000
+214% +$42.3M 0.7% 39
2023
Q2 		$20.2M Hold
3,009,678
– – 0.38% 43
2023
Q1 		$19.6M Hold
3,009,678
– – 0.44% 45
2022
Q4 		$25.7M Buy
+3,009,678
New +$19.5M 0.52% 44
2022
Q1 		– Sell
-1,742,186
Closed -$11.6M – 104
2021
Q4 		$11.6M Hold
1,742,186
– – 0.2% 78
2021
Q3 		$17.4M Hold
1,742,186
– – 0.24% 66
2021
Q2 		$53.8M Hold
1,742,186
– – 0.86% 37
2021
Q1 		$76M Hold
1,742,186
– – 1.15% 27
2020
Q4 		$80.7M Buy
+1,742,186
New +$58.2M 1.13% 27

Other funds holding SPRY

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RA Capital Management's SPRY Position: Q2 2026 in Review

RA Capital Management held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 10,860,977 shares worth $87M. The position accounts for 0.76% of the portfolio, ranked #27.

RA Capital Management first reported a position in SPRY in Q4 2020 and has held it in 20 quarters since. The position peaked at $190M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • RA Capital Management held 10,860,977 shares of ARS Pharmaceuticals worth $87M as of Q2 2026.
  • RA Capital Management left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up 0.76% of RA Capital Management's portfolio in Q2 2026, its #27 holding.
  • RA Capital Management first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
  • RA Capital Management's ARS Pharmaceuticals position peaked at $190M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.